Evidence map›Paper›PMID 38270883›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2024

Release of Antibodies and Cytokines from B Cells.

Shuang Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Shuang LiuDepartment of Pharmacology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan. liussmzk@m.ehime-u.ac.jp.
Ehime University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autoreactive B cells play a critical role in rheumatoid arthritis (RA). These cells differentiate into long-living memory B cells and autoantibody-producing plasma cells, and also present autoantigens to T cells to amplify misdirected immune responses. The therapeutic benefit of B-cell-deleting depleting therapies suggests that B cells are emerging as important factors in the pathogenesis of RA. Aiming at evaluation of the function of B cells, which are usually derived from peripheral blood of RA patients and healthy donors, it is possible to conduct a series of experiments, such as in vitro assessment of antibody production and BCR-mediated cytokine release. These techniques can also be applied for in vivo application.

Indexed as

Arthritis, RheumatoidB-LymphocytesAutoantibodiesCytokinesHumansMemory B CellsPlasma CellsAutoantibodiesCytokinesAntibody productionB cellCytokinePan B-cell purificationRheumatoid factor

Identifiers

PMID38270883
OpenAlexW4391232902

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.